Peterk Kaiser News Today

/PRNewswire/ -- BroadcastMed, the leading healthcare information marketplace that provides trusted clinical content, powerful engagement, and industry insights...

/PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery,...

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI...

BEDFORD, Mass., June 05, 2023 -- Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and... | June 5, 2023

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 ...

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and afliber...

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral... | January 25, 2023

Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Oculis Strengthens its Scientific Advisory Board with World-Leading

03.08.2022 - - CIMERLI is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI product sales expected in October 2022 - - COLUMBUS AMD trial was published in the journal Ophthalmology ... Seite 1